BOLT BIOTHERAPEUTICS INC (BOLT)

Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is headquartered in Redwood City, California and currently employs 100 full-time employees. The company went IPO on 2021-02-05. The firm's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. The company developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. The company is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Company Info

BOLT BIOTHERAPEUTICS INC

900 Chesapeake Drive

Redwood City CALIFORNIA 94063

P: 16506659295

CEO: Randall C. Schatzman

Employees: 100

Website: https://boltbio.com/